No association of MDM2 SNP309 with risk of glioblastoma and prognosis

被引：0
|
作者：
Soufiane El Hallani
Yannick Marie
Ahmed Idbaih
Mathieu Rodero
Blandine Boisselier
Florence Laigle-Donadey
François Ducray
Jean-Yves Delattre
Marc Sanson
机构：
[1] INSERM,Faculté de Médecine
[2] U711,Laboratoire d’Immunologie Cellulaire
[3] Biologie des Interactions Neurones & Glie,undefined
[4] Université Pierre et Marie Curie,undefined
[5] AP-HP,undefined
[6] Groupe Hospitalier Pitié-Salpêtrière,undefined
[7] Service de Neurologie Mazarin,undefined
[8] INSERM U543,undefined
来源：
Journal of Neuro-Oncology | 2007年 / 85卷
关键词：
Glioblastoma; MDM2; Polymorphism; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.
引用
收藏
页码：241 / 244
页数：3
相关论文
共 50 条
  • [1] No association of MDM2 SNP309 with risk of glioblastoma and prognosis
    El Hallani, Soufiane
    Marie, Yannick
    Idbaih, Ahmed
    Rodero, Mathieu
    Boisselier, Blandine
    Laigle-Donadey, Florence
    Ducray, Francois
    Delattre, Jean-Yves
    Sanson, Marc
    JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) : 241 - 244
  • [2] MDM2 SNP309 and risk of endometrial cancer
    Knappskog, Stian
    Lonning, Per Eystein
    TUMOR BIOLOGY, 2014, 35 (08) : 7285 - 7286
  • [3] MDM2 SNP309 and risk of endometrial cancer
    Knappskog, Stian
    Lonning, Per Eystein
    POLISH JOURNAL OF PATHOLOGY, 2013, 64 (01) : 69 - 70
  • [4] MDM2 SNP309 and risk of cervical cancer
    Knappskog, Stian
    Lonning, Per Eystein
    TUMOR BIOLOGY, 2014, 35 (07) : 6185 - 6186
  • [5] MDM2 SNP309 Confers Risk of Hereditary Melanoma
    Thunell, L. K.
    Bivik, C.
    Waster, P.
    Fredrikson, M.
    Stjernstrom, A.
    Synnerstad, I.
    Rosdahl, I.
    Enerback, C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S277 - S277
  • [6] Analysing the role of MDM2 SNP309 in patients with glioblastoma multiforme
    Akbarova, Yagut
    Dundar, Munis
    Akalin, Hilal
    Aslan, Dicle
    Canoz, Ozlem
    Ada, Yasin
    Yildiz, Oguz
    CURRENT OPINION IN BIOTECHNOLOGY, 2013, 24 : S98 - S98
  • [7] No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
    Campbell, Ian G.
    Eccles, Diana M.
    Choong, David Y. H.
    CANCER LETTERS, 2006, 240 (02) : 195 - 197
  • [8] MDM2 SNP309 and risk of endometrial cancer REPLY
    Zajac, Agnieszka
    Stachowiak, Grzegorz
    Pertynski, Tomasz
    Romanowicz, Hanna
    Wilczynski, Jacek
    Smolarz, Beata
    POLISH JOURNAL OF PATHOLOGY, 2013, 64 (01) : 70 - 70
  • [9] MDM2 SNP309 and cancer risk: a combined analysis
    Wilkening, Stefan
    Bermejo, Justo Lorenzo
    Hemminki, Kari
    CARCINOGENESIS, 2007, 28 (11) : 2262 - 2267
  • [10] Mdm2 SNP309 and bladder cancer risk.
    Stoehr, Robert
    Hitzenbichler, Florian
    Hammerschmied, Christine
    Rogenhofer, Michael
    Hartmann, Arndt
    CANCER RESEARCH, 2009, 69
12345